Oxford BioDynamics PLC - biotechnology firm focused on discovery and development of epigenetic biomarkers - Says its EpiSwitch Covid-19 severity test is available in the US and that it has seen increased interest following the resurgence of the Delta and Omicron variants. Says EpiSwitch can identify those with the greatest risk of experiencing critical, life-threatening disease because of a SARS-Cov-2 viral infection. Oxford BioDynamics expects to launch blood-based predictive tests in early 2022.
Current stock price: 34.00 pence
Year-to-date change: down 59%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Oxford Biodyn (OBD)